Literature DB >> 27987139

Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.

Lisa Arzt1, Iris Halbwedl2, Margit Gogg-Kamerer3, Helmut H Popper2.   

Abstract

Malignant pleural mesothelioma (MPM) is the most common primary tumor of the pleura. Its incidence is still increasing in Europe and the prognosis remains poor. We investigated the oncogenic function of signal transducer and activator of transcription 1 (STAT1) in MPM in more detail. A miRNA profiling was performed on 52 MPM tissue samples. Upregulated miRNAs (targeting SOCS1/3) were knocked-down using miRNA inhibitors. mRNA expression levels of STAT1/3, SOCS1/3 were detected in MPM cell lines. STAT1 has been knocked-down using siRNA and qPCR was used to detect mRNA expression levels of all JAK/STAT family members and genes that regulate them. An immunohistochemical staining was performed to detect the expression of caspases. STAT1 was upregulated and STAT3 was downregulated, SOCS1/3 protein was not detected but it was possible to detect SOCS1/3 mRNA in MPM cell lines. The upregulated miRNAs were successfully knocked-down, however the expected effect on SOCS1 expression was not detected. STAT1 knock-down had different effects on STAT3/5 expression. Caspase 3a and 8 expression was found to be increased after STAT1 knock-down. The physiologic regulation of STAT1 via SOCS1 is completely lost in MPM and it does not seem that the miRNAs identified by now, do inhibit the expression of SOCS1. MPM cell lines compensate STAT1 knock-down by increasing the expression of STAT3 or STAT5a, two genes which are generally considered to be oncogenes. And much more important, STAT1 knock-down induces apoptosis in MPM cell lines and STAT1 might therefore be a target for therapeutic intervention.

Entities:  

Keywords:  Apoptosis; Malignant pleural mesothelioma; STAT signaling; miRNA

Mesh:

Substances:

Year:  2016        PMID: 27987139     DOI: 10.1007/s12253-016-0157-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  34 in total

1.  [Negative regulation of the JAK/STAT: pathway implication in tumorigenesis].

Authors:  Lucile Espert; Isabelle Dusanter-Fourt; Mounira K Chelbi-Alix
Journal:  Bull Cancer       Date:  2005-10       Impact factor: 1.276

Review 2.  Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis.

Authors:  V S Romanov; V A Pospelov; T V Pospelova
Journal:  Biochemistry (Mosc)       Date:  2012-06       Impact factor: 2.487

Review 3.  New agents in the management of advanced mesothelioma.

Authors:  Nicholas J Vogelzang; Camillo Porta; Luciano Mutti
Journal:  Semin Oncol       Date:  2005-06       Impact factor: 4.929

Review 4.  STAT proteins: from normal control of cellular events to tumorigenesis.

Authors:  Valentina Calò; Manuela Migliavacca; Viviana Bazan; Marcella Macaluso; Maria Buscemi; Nicola Gebbia; Antonio Russo
Journal:  J Cell Physiol       Date:  2003-11       Impact factor: 6.384

5.  Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain.

Authors:  Iwona Sadzak; Melanie Schiff; Irene Gattermeier; Reingard Glinitzer; Ines Sauer; Armin Saalmüller; Edward Yang; Barbara Schaljo; Pavel Kovarik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

6.  Alternative activation of STAT1 and STAT3 in response to interferon-gamma.

Authors:  Yulan Qing; George R Stark
Journal:  J Biol Chem       Date:  2004-07-27       Impact factor: 5.157

7.  Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.

Authors:  G Reid; M E Pel; M B Kirschner; Y Y Cheng; N Mugridge; J Weiss; M Williams; C Wright; J J B Edelman; M P Vallely; B C McCaughan; S Klebe; H Brahmbhatt; J A MacDiarmid; N van Zandwijk
Journal:  Ann Oncol       Date:  2013-10-22       Impact factor: 32.976

8.  Suppressor of cytokine signaling 1 inhibits IFN-gamma inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation.

Authors:  Stefania Madonna; Claudia Scarponi; Ornella De Pità; Cristina Albanesi
Journal:  FASEB J       Date:  2008-06-12       Impact factor: 5.191

9.  microRNAs and genetic diseases.

Authors:  Nicola Meola; Vincenzo Alessandro Gennarino; Sandro Banfi
Journal:  Pathogenetics       Date:  2009-11-04

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  3 in total

Review 1.  Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance.

Authors:  Shuya Liu; Saber Imani; Youcai Deng; Janak L Pathak; Qinglian Wen; Yue Chen; Jingbo Wu
Journal:  Onco Targets Ther       Date:  2020-06-24       Impact factor: 4.147

2.  CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.

Authors:  Xue-Tang Mo; Thomas Ho-Yin Leung; Hermit Wai-Man Tang; Michelle Kwan-Yee Siu; Peter Kok-Ting Wan; Karen Kar-Loen Chan; Annie Nga-Yin Cheung; Hextan Yuen-Sheung Ngan
Journal:  Br J Cancer       Date:  2020-06-08       Impact factor: 7.640

Review 3.  Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis.

Authors:  Qi Chen; Jianjun Lv; Wenwen Yang; Baoping Xu; Zheng Wang; Zihao Yu; Jiawei Wu; Yang Yang; Yuehu Han
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.